Musgrove Park Hospital, Taunton, UK.
Department of Chemical Engineering & Biotechnology, University of Cambridge, Cambridge, UK.
Adv Exp Med Biol. 2020;1260:175-191. doi: 10.1007/978-3-030-42667-5_8.
There have been repeated failures of clinical studies in the development of new efficacious treatments for Alzheimer's disease. This may be due to the fact that Alzheimer's disease is a heterogeneous disorder caused by person-to-person differences in genetic background, epigenetic profiles, environmental triggers, or the presence of other diseases. Furthermore, most Alzheimer's disease patients are diagnosed in the middle to late stages of the illness, when irreversible damage to the brain has already occurred. With this in mind, a strategy is presented involving identification and implementation of biomarker tests for diagnosis during the prodromal or early stages of the disease. In addition, it is proposed that targeting specific components of the amyloid deposition, tau oligomerization and neuroinflammation pathways may lead to improved outcomes in clinical studies.
在开发新的阿尔茨海默病有效治疗方法的临床研究中，已经出现了多次失败。这可能是由于阿尔茨海默病是一种异质性疾病，由遗传背景、表观遗传谱、环境触发因素或其他疾病的个体差异引起。此外，大多数阿尔茨海默病患者在疾病的中晚期被诊断出来，此时大脑已经发生了不可逆转的损伤。考虑到这一点，提出了一种策略，包括在疾病的前驱期或早期阶段识别和实施生物标志物测试进行诊断。此外，有人提出，针对淀粉样蛋白沉积、tau 寡聚化和神经炎症途径的特定成分，可能会导致临床研究的结果得到改善。
